Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution

View ORCID ProfileMaria E. Monberg, Heather Geiger, View ORCID ProfileJaewon J. Lee, Roshan Sharma, View ORCID ProfileAlexander Semaan, Vincent Bernard, Daniel B. Swartzlander, Bret M. Stephens, Ken Chen, Matthew HG Katz, View ORCID ProfileNicolas Robine, Paola A. Guerrero, Anirban Maitra
doi: https://doi.org/10.1101/2021.04.13.439717
Maria E. Monberg
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2University of Texas MD Anderson Cancer Center Graduate School of Biomedical Sciences, Houston, TX, USA
3Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maria E. Monberg
  • For correspondence: memonberg@mdanderson.org
Heather Geiger
4New York Genome Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaewon J. Lee
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
6Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jaewon J. Lee
Roshan Sharma
4New York Genome Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Semaan
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexander Semaan
Vincent Bernard
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel B. Swartzlander
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bret M. Stephens
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Chen
5Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew HG Katz
6Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Robine
4New York Genome Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicolas Robine
Paola A. Guerrero
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anirban Maitra
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Intratumoral heterogeneity (ITH) is a hallmark of cancer. The advent of single-cell technologies has helped uncover ITH in a high-throughput manner in different cancers across varied contexts. Here we apply single-cell sequencing technologies to reveal striking ITH in assumptively oligoclonal pancreatic ductal adenocarcinoma (PDAC) cell lines. Our findings reveal a high degree of both genomic and transcriptomic heterogeneity in established and globally utilized PDAC cell lines, custodial variation induced by growing apparently identical PDAC cell lines in different laboratories, and profound transcriptomic shifts in transitioning from 2D to 3D spheroid growth models. Our findings also call into question the validity of widely available immortalized, non-transformed pancreatic lines as contemporaneous “control” lines in experiments. Further, while patient-derived organoid (PDOs) are known to reflect the cognate in vivo biology of the parental tumor, we identify transcriptomic shifts during ex vivo passage that might hamper their predictive abilities over time. The impact of these findings on rigor and reproducibility of experimental data generated using established preclinical PDAC models between and across laboratories is uncertain, but a matter of concern.

Competing Interest Statement

A.M. receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and monitored by the UTMDACC Conflict of Interest Committee. A.M. is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to ThriveEarlier Detection.

Footnotes

  • Funding: A.M. is supported by the MD Anderson Pancreatic Cancer Moon Shot Program, the Khalifa Bin Zayed Al-Nahyan Foundation, and the National Institutes of Health (NIH U01CA196403, U01CA200468, P50CA221707). J.J.L. is supported by the NIH (T32CA009599). A.S. is supported by the German Research Foundation (SE- 2616/2–1). V.B. is supported by the NIH (U54CA096300, U54CA096297, and T32CA217789)

  • Disclosures: A.M. receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and monitored by the UTMDACC Conflict of Interest Committee. A.M. is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to ThriveEarlier Detection.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 13, 2021.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution
Maria E. Monberg, Heather Geiger, Jaewon J. Lee, Roshan Sharma, Alexander Semaan, Vincent Bernard, Daniel B. Swartzlander, Bret M. Stephens, Ken Chen, Matthew HG Katz, Nicolas Robine, Paola A. Guerrero, Anirban Maitra
bioRxiv 2021.04.13.439717; doi: https://doi.org/10.1101/2021.04.13.439717
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution
Maria E. Monberg, Heather Geiger, Jaewon J. Lee, Roshan Sharma, Alexander Semaan, Vincent Bernard, Daniel B. Swartzlander, Bret M. Stephens, Ken Chen, Matthew HG Katz, Nicolas Robine, Paola A. Guerrero, Anirban Maitra
bioRxiv 2021.04.13.439717; doi: https://doi.org/10.1101/2021.04.13.439717

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cancer Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (3513)
  • Biochemistry (7359)
  • Bioengineering (5338)
  • Bioinformatics (20305)
  • Biophysics (10034)
  • Cancer Biology (7763)
  • Cell Biology (11329)
  • Clinical Trials (138)
  • Developmental Biology (6443)
  • Ecology (9968)
  • Epidemiology (2065)
  • Evolutionary Biology (13346)
  • Genetics (9364)
  • Genomics (12598)
  • Immunology (7718)
  • Microbiology (19058)
  • Molecular Biology (7452)
  • Neuroscience (41104)
  • Paleontology (300)
  • Pathology (1233)
  • Pharmacology and Toxicology (2141)
  • Physiology (3171)
  • Plant Biology (6867)
  • Scientific Communication and Education (1275)
  • Synthetic Biology (1899)
  • Systems Biology (5320)
  • Zoology (1090)